H. Enzmann

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
H G Enzmann, H. Enzmann, Harald G Enzmann, H Enzmann, Harald G. Enzmann, Harald Enzmann
Publication record
80 papers · 1,360 citations · H-index 21

PAPERS

P04.03 Cancer immunotherapies, companion diagnostics and precision medicine
20220 citationsauthor #3
The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
202219 citationsauthor #8
Attention for sex in COVID-19 trials: a review of regulatory dossiers
20226 citationsauthor #5
The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation
202110 citationsauthor #10
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
20215 citationsauthor #7
The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
20217 citationsauthor #10
The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
20216 citationsauthor #9
The European Medicines Agency Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
20211 citationsauthor #6
The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
202182 citationsauthor #2
The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
202117 citationsauthor #7
The Rat Liver Hepatocellular-Altered, Focus-Limited Bioassay for Chemicals with Carcinogenic Activity
20211 citationsauthor #2
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
202135 citationsauthor #8
The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
202113 citationsauthor #8
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
202123 citationsauthor #6
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
20216 citationsauthor #9
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
20201 citationsauthor #15
Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?
202024 citationsauthor #3
EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma
20200 citationsauthor #20
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
202018 citationsauthor #13
The European Medicines Agency review of daratumumab (Darzalex) for the treatment of adult patients newly diagnosed with multiple myeloma.
20206 citationsauthor #14
The EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
202037 citationsauthor #8
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
201951 citationsauthor #2
Added therapeutic benefit and drug licensing
201912 citationsauthor #2
Companion Diagnostics and Biomarker Tests in the European Medicines Agency’s Assessment of Medicinal Products
20193 citationsauthor #1
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
201963 citationsauthor #4
Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience.
20197 citationsauthor #5
Acknowledgement to Referees
20170 citationsauthor #9
New trends and challenges in the European regulation of innovative medicines.
201610 citationsauthor #1
The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.
201622 citationsauthor #1
Development of Innovative Medicines for European Patients and Impactof Brexit
20162 citationsauthor #1
Dose-dependent induction of preneoplastic lesions by the tobacco-specific nitrosamine carcinogen NNK in the in ovo carcinogenicity assessment (IOCA) assay.
20146 citationsauthor #1
Carcinogenicity of Chemicals: Assessment and Human Extrapolation
201412 citationsauthor #3
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
20146 citationsauthor #8
The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
20149 citationsauthor #3
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
201439 citationsauthor #8
Tyrosine kinase inhibitors becoming generic drugs – risks and chances from a regulatory perspective
20142 citationsauthor #8
Enzmann et al Arch Geschwulstforsch 60, 283-287, 1990
20140 citationsauthor #2
The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
20148 citationsauthor #6
Perspectives Florbetapir ( 18 F) for brain amyloid positron emission tomography: Highlights on the European marketing approval
20142 citationsauthor #6
Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval
20145 citationsauthor #8
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
20135 citationsauthor #1
Inter-laboratory comparison of turkey in ovo carcinogenicity assessment (IOCA) of hepatocarcinogens.
201310 citationsauthor #1
[Treatment of sequelae of childhood obesity].
20130 citationsauthor #1
Current european regulatory perspectives on insulin analogues
20112 citationsauthor #1
[The therapy of obesity in children and adolescents : An insufficiently researched area?].
20110 citationsauthor #1
Production of liver preneoplasia and gallbladder agenesis in turkey fetuses administered diethylnitrosamine
201119 citationsauthor #5
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
200956 citationsauthor #5
[Marketing authorization for pharmaceuticals: the necessity of European collaboration].
20080 citationsauthor #2
Principles of Testing for Carcinogenic Activity
200738 citationsauthor #3
Non-persisting early foci of altered hepatocytes induced in rats by N-nitrosomorpholine
20044 citationsauthor #1
Prevalidation of a Rat Liver Foci Bioassay (RLFB) Based on Results from 1600 Rats: A Study Report
200316 citationsauthor #7
In ovo carcinogenicity assay (IOCA): evaluation of mannitol, caprolactam and nitrosoproline
200214 citationsauthor #2
Bioassay of mannitol and caprolactam and assessment of response to diethylnitrosamine in heterozygous p53-deficient (+/-) and wild type (+/+) mice
200114 citationsauthor #4
N-Nitrosomorpholine induced alterations of unscheduled DNA synthesis, mitochondrial DNA synthesis and cell proliferation in different cell types of liver, kidney, and urogenital organs in the rat.
200114 citationsauthor #4
No induction of neoplasia or proliferation in p53-hemizygous mice after exposure to 4- -1- -1-butanone and diethylnitrosamine
20010 citationsauthor #5
Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic.
200113 citationsauthor #3
Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver.
199920 citationsauthor #1
Nonlinearity of nuclear enlargement in hepatocytes induced by the carcinogen N'-nitrosomorpholine in Ovo.
19994 citationsauthor #2
Carcinogen-induced Mitochondrial DNA Damage in the In Ovo Model.
19985 citationsauthor #4
Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay.
199832 citationsauthor #1
Calcium Channel Blockers and the Risk of Cancer: A Preclinical Assessment
19987 citationsauthor #3
Short- and intermediate-term carcinogenicity testing--a review. Part 2: available experimental models.
199821 citationsauthor #1
The significance of mouse liver tumor formation for carcinogenic risk assessment: results and conclusions from a survey of ten years of testing by the agrochemical industry.
199754 citationsauthor #2
The in ovo carcinogenicity assay (IOCA): a review of an experimental approach for research on carcinogenesis and carcinogenicity testing.
199713 citationsauthor #1
Accumulation of p53 protein in chemically induced oval cells during early stages of rodent hepatocarcinogenesis.
199512 citationsauthor #2
Rapid Induction of Preneoplastic Liver Foci in Embryonal Turkey Liver by Diethylnitrosamine
199514 citationsauthor #1
Dose dependence of diethylnitrosamine-induced nuclear enlargement in embryonal turkey liver.
199513 citationsauthor #1
Glycogen phosphorylase hyperactive foci of altered hepatocytes in aged rats
19928 citationsauthor #1
Foci of altered hepatocytes induced in embryonal turkey liver.
199228 citationsauthor #1
Dietary fructose enhances the development of atypical acinar cell nodules in the pancreas of rats pretreated with N-nitrosomorpholine.
19905 citationsauthor #1
Enhancement of hepatocarcinogenesis in rats by dietary fructose.
198930 citationsauthor #1
Unusual histochemical pattern in preneoplastic hepatic foci characterized by hyperactivity of several enzymes
198928 citationsauthor #1
Significance of Sequential Cellular Changes Inside and Outside Foci of Altered Hepatocytes During Hepatocarcinogenesis∗
198993 citationsauthor #2
Cellular Differentiation During Neoplastic Development in the Liver
19886 citationsauthor #2
Elevation of Glucose-6-Phosphate in Early Stages of Hepatocarcinogenesis Induced in Rats by N-Nitrosomorpholine
198812 citationsauthor #1
Simple elementary method for the quantification of focal liver lesions induced by carcinogens.
198738 citationsauthor #1
Morphometric study of alterations of extrafocal hepatocytes of rat liver treated with N-Nitrosomorpholine
198717 citationsauthor #1
Potential significance of phenotypic heterogeneity of focal lesions at different stages in hepatocarcinogenesis.
198758 citationsauthor #1
Preneoplastic Lesions as Indicators of the Carcinogenic Risk Caused by Chemicals
19872 citationsauthor #2
Tigroid cell foci and neoplastic nodules in the liver of rats treated with a single dose of aflatoxin B1.
198560 citationsauthor #3

TIMELINE

1985 60 citations

1987 115 citations

1988 18 citations

1989 151 citations

1990 5 citations

1992 36 citations

1995 39 citations

1997 67 citations

1998 65 citations

1999 24 citations

2001 41 citations

2002 14 citations

2003 16 citations

2004 4 citations

2007 38 citations

2008 0 citations

2009 56 citations

2011 21 citations

2013 15 citations

2014 89 citations

2016 34 citations

2017 0 citations

2019 136 citations

2020 86 citations

2021 206 citations

2022 25 citations

COAUTHOR MAP

CONCEPT FOOTPRINT